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Nature and extent of glomerular injury induced by cyclosporine in
heart transplant patients. We sought to clarify whether low-dose cy-
closporine (5.0 2.2 mg/kglday) given for more than two years to
prevent cardiac graft rejection induced glomerular injury and to quan-
tify the extent of the lesions. After renal hemodynamic studies, renal
biopsy specimens were obtained from 10 patients on cyclosporine and
analyzed by a novel morphometric technique consisting of a tridimen-
sional reconstruction of the glomerular tuft. Autopsy kidney specimens
from three patients with no clinical history of renal disease, and from
four patients who died with dilatative cardiomyopathy served as
controls. The glomerular filtration rate and renal plasma flow were
significantly depressed below normal values in transplant recipients
given cyclosporine, averaging 35 8 and 325 94 mI/mm/I .73 m2,
respectively. Conventional light microscopy of specimens from con-
trols and from patients who died with dilatative cardiomyopathy did not
reveal renal structural abnormalities. By contrast kidney specimens
from cyclosporine-treated patients had obliterative arteriolopathy and
ischemic-type changes, with thickening and wrinkling of glomerular
capillary wall. Morphometrical analysis of 28 control glomeruli and 40
glomeruli from patients with dilatative cardiomyopathy showed glomer-
ular capillary tuft volumes (VCT) ranging between 1.2 and 2.3 m3 x
10-6, whereas of 102 glomeruli from cyclosporine-treated patients
42.1% had VCT lower than 1.2 m3 x 106 and 24.4% VCT higher than
2.3 m3 x 106. Tridimensional reconstruction revealed that 40.1% of
glomeruli of cyclosporine-treated patients but none of controls were
affected by global or segmental sclerosis which was confined to glomer-
uli with small and normal VCT. Thus, only 2 out of 25 large glomeruli
had sclerotic changes involving, however, less then 0.2% of VCT. We
conclude that cyclosporine given for more than two years induced
moderate to severe renal failure in all patients associated with obliter-
ative arteriolopathy and glomerular ischemia. In these patients two
subpopulations of glomeruli of abnormal size emerged. Lower than
normal glomeruli had global or segmental sclerosis. Thus, cyclosporine
should be better employed for diseases in which the expected benefits
are likely to outweigh its potential for inducing major glomerular
functional and structural damage.
Cyclosporine has improved allograft survival in renal [I],
liver [2], heart [31 and pancreas [4] transplantation. More
recently cyclosporine has also been advocated as a promising
therapeutic agent for the prevention of graft versus host disease
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in bone marrow transplantation [5] and for the treatment of
some autoimmune diseases including uveitis [6], systemic lupus
erythematosus [7], rheumatoid arthritis [8] and various forms of
glomerulonephritis [9,10].
However, this drug has major side effects that considerably
limit its use in humans, mainly because of liver and renal
toxicity [11—13].
One of the main issues related to cyclosporine-induced renal
dysfunction is whether this effect is confined to the use of
"high" doses, as in the early stages of heart transplantation
(that is, 10 to 17 mg/kg/day) [14] or whether it also occurs with
the much lower doses that are currently employed to prevent
kidney [15] and heart [16] allograft rejection (3 to 7 mg/kg/day).
An additional issue that has not been clarified so far is whether
cyclosporine nephrotoxicity is reversible or progressive in
nature so that terminal renal failure may eventually occur in
patients treated for more than two years [17]. The data so far
available on this matter are conflicting [17—19].
Recent studies performed in heart transplant patients [17]
showed that two years of cyclosporine therapy caused a decline
in renal plasma flow (RPF) and glomerular filtration rate (GFR)
which was not reversible, and was associated with signs of renal
damage which at a given point progressed even if cyclosporine
was stopped. At variance, Bantle and coworkers [19] suggested
that although cyclosporine treatment produced a decrease in
renal function the underlying disease was not necessarily pro-
gressive. However, most studies on cyclosporine-induced renal
dysfunction did not correlate renal function deterioration with
renal structural changes. This is particularly true for glomerular
abnormalities which in the majority of the studies so far
available have only been investigated by functional measure-
ments.
The present study was designed to correlate renal function
deterioration with morphological signs of renal damage in
patients with cardiac transplant given cyclosporine for more
than two years. Moreover we wanted to better clarify the nature
of cyclosporine-induced glomerular damage which so far has
not been properly investigated. To this purpose heart transplant
patients underwent a renal biopsy and the specimens were
analyzed by a novel morphometric technique consisting of a
tridimensional reconstruction of the glomerular tuft [20]. This
technique allowed to evaluate glomerular volume abnormalities
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and precisely define the extent and the spatial distribution of
glomerular changes.
Methods
Subjects
The first ten patients (3 female, 7 male; mean age at the time
of the study: 46.9 years; range 23 to 57 years) who survived
more than two years after cardiac transplantation at the Divi-
sion of Cardiac Surgery of the Ospedali Riuniti di Bergamo
were studied. All patients had been transplanted because of
dilatative cardiomyopathy, which was of ischemic etiology in
four and idiopathic in six. At the time of the study all patients
were in NYHA class I. The mean duration of follow up at time
of study was 37.5 months (range: 31 to 48). At time of
transplantation the mean oral loading dose of cyclosporine was
7.9 3.1 mg/kg/day. Patients were then immunosuppressed
with cyclosporine combined with prednisone or azathioprine,
or both; the mean time-averaged dose of cyclosporine along the
follow up was 4.8 1.6 mg/kg/day.
Study design
The study protocol, approved by our institutional ethical
committee, was illustrated in detail to all patients before admis-
sion, and oral informed consent to take part in the study was
obtained in each instance. Patients were excluded from the
study if a contraindication to percutaneous renal biopsy was
present, that is, uncontrolled hypertension, hemorrhagic dia-
thesis (as defined by one or more of the following: template
bleeding time > 10 minutes; platelet count <l00,000/tl; APT!'
and PT greater than 1.5 times the control values), solitary
kidney, hydronephrosis, multiple renal cysts. Antiplatelet
agents were discontinued for seven days before admission in all
patients receiving such therapy. Patients were admitted to the
Division of Nephrology of the Ospedali Riuniti and on the first
hospital day renal function was determined by the clearances of
inulin and para-aminohippuric acid (PAH). On the day follow-
ing the physiologic studies all patients underwent needle renal
biopsy and then discharged after a full day of bed rest.
Renal clearance studies
Each cyclosporine recipient underwent renal clearance
study. In brief, the clearance of inulin and PAH was performed
under a steady state of water diuresis induced by oral water
loading. A priming solution containing 10% inulin and 20% PAH
was infused, followed by continuous administration of inulin
and PAH to maintain constant plasma concentrations of ap-
proximately 15 and 1.5 mg/dl, respectively. After an equilibra-
tion period of about 60 minutes, three exactly timed urine
collections of 30 minutes each were performed. Blood pressure
was measured periodically throughout the study. Urine was
collected by spontaneous voiding, and blood was collected at
the beginning and at the end of each clearance period. Inulin
and PAH concentrations in plasma and urine samples were
determined using methods previously described [21, 22]. GFR
was calculated as the urinary clearance of inulin corrected for
body surface area. Effective RPF was calculated by dividing the
urinary clearance of PAH by an assumed extraction ratio of 0.8
[23].
Pathological studies
All 10 patients on cyclosporine underwent a percutaneous
renal biopsy 31 to 48 months post-transplantation, on the day
following the physiological studies. Renal tissue was obtained
from renal autopsy specimen of four patients, matched for age,
sex, and incidence of hypertension, who died with severe heart
failure, due to dilatative cardiomyopathy. Since patients with
chronic heart failure were on anticoagulant therapy, it was
considered unethical to interrupt the anticoagulation to perform
renal biopsy; therefore autopsy specimens were used as control
material. Autopsy kidney specimens from three patients with
no clinical history of heart and renal diseases and with normal
renal function provided normal control values. Further compar-
ison was obtained by performing morphometric analysis on a
specimen of normal renal biopsy material.
Renal tissue was processed for light microscopy by fixation in
Dubosq-Brazil fluid and embedding in paraffin. Pathological
examination and semiquantitative assessment of renal damage
were done in at least 18 sections. In cyclosporine-treated
patients a total number of 269 glomeruli was evaluated including
superficial and juxtamedullary glomeruli. The number and the
percentage of globally and segmentally sclerotic glomeruli was
determined. Focal and segmental sclerotic lesions were defined
as an increase of mesangial matrix substance associated with
capillary wall collapse. The sclerotic lesions might or might not
be associated with adhesion to Bowman's capsule. The estima-
tion of ischemic glomerular lesions, characterized by thickening
and wrinkling of glomerular capillary wall and by thickening of
Bowman's capsule, was obtained semiquantitatively using a
scoring system from 0 to 3+ (0 = no changes; I + = <30% of
glomeruli affected; 2+ = 30 to 60% of glomeruli affected; 3+ =
> 60% of glomeruli affected). The hyperplasia of juxtaglomer-
ular apparatus was also graded from 0 to 3+ (0 = no changes,
1+ = mild, 2+ = moderate, 3+ = severe). Interstitial fibrosis
and tubular atrophy were graded from 0 to 3+ (0 =nochanges,
1+ = changes in <25% of the biopsy specimens, 2+ = changes
affecting 25% to 50% of biopsy specimens, 3+ = changes
affecting > 50% of the biopsy specimens). Vascular lesions
were evaluated as the presence of PAS positive material per-
meating the artenolar wall and narrowing or occluding the
vascular lumen or mucoid thickening of intima resulting in a
narrowing of vascular lumens and were graded from 0 to 3+ (0
= no changes, 1+ mild, 2+ = moderate, 3+ = severe),
Sclerotic changes in the arteries were graded from 0 to 3+ (0
no changes, 1+ = mild, 2+ = moderate, 3+ severe).
Morphometric analysis
Glomerular volume was estimated using serial section recon-
struction of individual glomeruli [201. For each cyclosporine
recipient, control, and patient with dilatative cardiomyopathy
81 consecutive sections (4 s thick) were cut and stained with
periodic-acid Schiff's reagent (PAS). A section approximately
located in the middle of the tissue, hereafter referred as
"starting section", was identified. The profiles of the Bow-
man's capsule, capillary tuft, and sclerotic changes of all
glomeruli in this section were manually outlined using a drawing
tube (Zeiss, Germany) mounted on the microscope at the final
magnification of x 322. This procedure was repeated for each
glomerulus in all the sections preceding and following the
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Fig. 1. Serum creatinine in 10 patients with cardiac transplant at 4
month time intervals after transplantation (solid dots and line). Col-
umns represent the average cyclosporine dose at the same time points.
*D < 0.05 vs. month 0.
"starting section" until it completely disappeared. Only gb-
meruli entirely reconstructed were considered for morphomet-
rical analysis (102 gbomerubi from cyclosporine recipients, 28
from controls, and 40 from patients with dilatative cardiomy-
opathy). Surface area of each outline of Bowman's capsule,
capillary tuft, and sclerotic regions were determined with
stereological methods [24] using a grid 26 x 29 points. Volume
of Bowman's capsule, capillary tuft (VCT) and sclerotic regions
for each glomerulus was calculated as:
n
V = ( A1) d
1=1
where A1 is the surface area of the outlines of Bowman's
capsule, capillary tuft, and glomerular sclerotic regions, d is the
section thickness and n is the number of sections for each
glomerulus. The percentage of VCT affected by sclerosis was
then calculated for each individual glomerulus.
Cyclosporine immunoassay
Cyclosporine trough concentrations were determined on
whole blood by a specific radioimmunoassay employing a
monoclonal antibody (Incstar Corporation, Minnesota, USA).
Statistical analysis
All results are expressed as mean SD. Data were analyzed
using unpaired Student's t-test and linear regression analysis.
Serum creatinine data were analyzed using one-way analysis of
variance and Dunnett test for multiple comparisons [25J. Sta-
tistical significance level was defined as P < 0.05.
Results
Clinical and laboratory findings
Mean serum creatinine of study population at the time of
transplantation was 105 8 mol/liter. Figure 1 shows the
Fig. 2. Systolic and diastolic blood pressure in cardiac transplant
patients during 36 months of follow-up. Shaded areas represent stan-
dard deviations from the mean.
mean serum creatinine at various time intervals after transplan-
tation together with the mean daily dose of cyclosporine. Mean
serum creatinine concentration significantly increased (P <
0.05) after transplantation and remained elevated above pre-
transplant value during the entire observation period. Two
patients had a transient rise of serum creatinine above 200
smol/liter during the course of their follow up, but no episodes
of acute renal failure were recorded during the entire period of
follow up. By the time of renal biopsy, mean serum creatinine
concentration of patients in the study group was 140 44
imol/liter. This value is comparable to that of other patients
who received cardiac transplant at our Institution and had been
treated with cyclosporine for a similar length of time. Only one
patient had measurable proteinuria (0.7 g124 hr) at time of
transplantation. At the time of renal biopsy seven patients were
proteinuric, all of them with urinary protein excretion less than
I g/24 hr.
Both systolic and diastolic blood pressure increased slightly
after transplantation in most of the patients; seven of them
required antihypertensive therapy, which consisted of low
doses of captoprib or nifedipine. However as shown in Figure 2
blood pressure was only moderately elevated during three years
of follow up. At the time of the study mean arterial blood
pressure was 142 12 mm Hg over 89 8 mm Hg.
Renal function studies
Renal functional parameters measured in cyclosporine recip-
ients are summarized in Table 1. Patients were receiving a dose
of cyclosporine ranging from 3 to 10 mg/kglday. Corresponding
trough concentrations of immunoassayable cyclosporine were
on average 255 151 nglml. In all cyclosporine recipients mean
arterial pressure was in the normal range. In each patient mean
RPF was markedly lower than normal values, averaging 325
mb/min/l.73 m2. Similarly GFR was reduced as compared to
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Table 1. Physiologic findings of cyclosporine recipients
Mean Range
Cyclosporine dose mg/kg/24 hr 5 3—10
Cyclosporine trough ng/ml 255 84—600
MAP mm Hg 108 87-119
GFR mi/mini] .73 m2 35 18—47
RPF mlimin/l.73 m2 325 207—472
Filtration fraction % 10 7—15
Proteinuria g/24 hr 0.2 0—0.45
Abbreviations are: MAP, mean arterial pressure; GFR, glomerular
filtration rate; RPF, renal plasma flow.
normal values, averaging 35 ml/minil.73m2 (Table 1). Since the
decline in GFR exceeded that in RPF, filtration fraction was
lower than normal.
Morphological findings
All the 10 cardiac transplant patients treated with cyclospo-
nne had major changes at renal biopsy. By contrast renal
autopsy specimens from controls and from patients who died
with dilatative cardiomyopathy did not reveal renal structural
abnormalities.
Light microscopic findings in cyclosporine patients are sum-
marized in Table 2. The spectrum of changes was rather broad
and involved all anatomical structures of the kidney. Seventy-
eight glomeruli of the 269 examined (28.9%) exhibited global (N
= 48, 17.8%) or segmental (N = 30, 11.1%) sclerosis. Global
glomerular sclerosis was present in all patients but one involv-
ing 5.8% to 44.4% of the glomeruli, while segmental sclerotic
lesions were observed in all but two patients. Most glomeruli
disclosed ischemic changes characterized by thickening and
wrinkling of glomerular capillary wall and by thickening of
Bowman's capsule. A striking juxtaglomerular apparatus hy-
perplasia was evident in all glomeruli examined from all patients
and ranged from 1+ to 3+ (average 1.8 0.6). All specimens
exhibited a pattern of tubular atrophy and interstitial fibrosis, in
some cases the changes being nearly diffuse, but most showing
narrow striped forms. Interstitial chronic inflammatory reaction
was unremarkable. Vascular lesions also included the so-called
form of cyclosporine arteriolopathy [161 that was detected in all
cyclosporine recipients but one and averaged 1.33 0.50 (mean
score). Arteriolar abnormalities consisted of subintimal and
medial hyaline deposits with focal replacement of pericytes by
PAS-positive hyaline material.
Results of morphometrical analysis are reported in Figure 3.
Mean VCT averaged 1.74 0.30 sm3 x 106 in controls and
1.58 0.29 m3 x 106 in patients died with dilatative
cardiomyopathy, values comparable to those found in cyclo-
sporine recipients (1.66 0.97 tm3 X l0_6). In a specimen of
normal renal biopsy material the mean VCT was 1.43 0.34
x 106.
By contrast the distribution of VCT around the mean was
markedly different in controls, patients with dilatative cardio-
myopathy, and cyclosporine patients. VCT of glomeruli from
controls and patients with dilatative cardiomyopathy ranged
between 1.2 and 2.3 m3 x 10_6, whereas in cyclosporine-
treated patients VCT ranged from 0.28 to 4.81 sm3 X 106.
Forty-two percent of glomeruli had a VCT < 1.2 m3 x 10—6,
and 24.5% were > 2.3 m3 x icr6, showing that, as compared
to control glomerular VCT, two additional subsets of glomeruli
with reduced or enlarged VCT were present in the specimens
from cyclosporine-treated patients. Similar results were ob-
tained for Bowman's capsule volume (Fig. 4).
Serial section analysis did not show sclerotic lesions in
specimens taken from controls and patients with dilatative
cardiomyopathy. By contrast, tridimensional reconstruction of
102 glomeruli from cyclosporine-treated patients revealed that
40.1% of glomeruli were affected by sclerosis (8.8% global
sclerosis, 3 1.3% segmental sclerosis). Of note, this percentage
was higher than that estimated in the same patients by conven-
tional histological analysis, which averaged 28.9%. Figure 5
illustrates the relationship between volume of glomerular scle-
rotic lesions and CT for each individual glomerulus in patients
on cyclosporine. No significant correlation (r =0.07, P = 0.646)
was found between VCT and sclerosis volume. However, gb-
meruli with VCT larger than normal (VCT > 2.3 m3 x 106)
were almost never affected by sclerotic changes. Sclerotic
lesions were confined to glomeruli with small and normal CT•
Thus for small glomeruli (VCT < 1.2 prn x 10—6) 28 out of 43
had sclerotic changes, for normal glomeruli (VCT 1.2 to 2.3 m3
x 10—6) 12 out 34, whereas for large glomeruli (VCT> 2.3 m3
x 10—6) only 2 out 25 had sclerotic changes that however
involved less than 0.2% of VCT volume.
To establish whether the reduction in GFR observed in these
patients was related to the degree of glomerulosclerosis, in
seven patients in which the number of glomeruli used for
morphometrical analysis was greater than 10, linear regression
analysis was applied to correlate the observed values of GFR
with the percent of VCT affected by sclerosis. No significant
correlation was found (r = 0.53, P = 0.219) between these two
parameters suggesting that fall in GFR, as measured in this
study, is not completely accounted for the degree of glomeru-
losclerosis in a given patient.
Figure 6 shows the correlation between the time-averaged
dose of cycbosporine during the follow up in individual patients,
expressed in mg/kg/day, and the mean capillary tuft volume in
their renal biopsy. Although a trend exists to smaller glomeruli
in patients treated with higher doses of cyclosporine, regression
analysis did not reached a significance level.
Discussion
The present study shows that patients on cyclosporine for
more than two years to prevent the reject of heart transplant
had a severe nephropathy. Renal functional studies showed a
marked reduction in RPF and GFR with a proportional greater
fall in GFR. This was associated with renal structural
changes—at renal biopsy—that included global or segmental
glomerulosclerosis, signs of glomerular ischemia, juxtaglomer-
ular apparatus hyperplasia, tubular atrophy, interstitial fibrosis,
and hyaline deposits in the arteriolar walls.
Some of these changes had been previously recognized also
in the kidneys of patients receiving cyclosporine after liver
transplantation [26], or to treat autoimmune diseases such as
uveitis [27]. However, one might argue that the lesions ob-
served in our patients may not have been entirely related to the
toxic effect of the drug but, at least in part, to a preexisting renal
damage possibly related to chronic heart failure. However,
renal autopsy specimens taken from patients with severe heart
failure and elevated serum creatinine who died before a heart
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Table 2. Renal histopathology by conventional analysis
Months on
cyclosporine
OS SG
JGAH WCW BCT IF TA A CsA-AA%
B.B.
A.G.
G.C.
F.A.
P.P.
S.G.
G.D.
F.S.
T.A.
C.M.
38
39
42
34
41
38
34
48
37
34
34.8
41.1
44.4
43.7
0
9.6
5.8
23.5
7.4
22.7
8.7
11.7
0
6.8
7.3
0
17.6
17.6
12.7
20.4
2+
2+
1+
1+
2+
3+
1+
2+
2+
2+
0
1+
1+
1+
1+
2+
1+
1+
1+
1+
1+
1+
1+
1+
2+
1+
1+
2+
1+
1+
2+
1+
2+
2+
2+
2+
2+
2+
1+
2+
2+
1+
2+
2+
2+
2+
2+
2+
1+
2+
0
0
1+
1+
2+
1+
0
1+
1+
0
1+
2+
N-A
2+
1+
1+
1+
1+
2+
1+
Abbreviations are: OS, global sclerosis; SO, segmental sclerosis; JGAH, juxtaglomerular apparatus hyperplasia; WCW, wrinkling of capillary
wall; BCT, Bowman's capsule thickening; IF, interstitial fibrosis; TA, tubular atrophy; A, arteriosclerosis; CsA-AA, cyclosporine artenolopathy;
N-A, no arterioles available.
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transplant became available did not show structural changes.
This would suggest that glomerular, interstitial and vascular
lesions observed in our cyclosporine patients are likely due to
the peculiar renal effect of the drug, rather than a consequence
of the underlying hemodynamic changes possibly related to the
heart failure.
Similarly, previous studies in autopsied patients who had
died with heart failure and reduced GFR [28], as well as more
recent reports on heart transplant patients given azathioprine
instead of cyclosporine [14, 17], failed to demonstrate glomer-
ular sclerosis, tubulointerstitial fibrosis or hyaline arteriolopa-
thy. All these considerations reinforce the concept that renal
structural lesions in cyclosporine-treated patients are likely the
consequence of the chronic use of cyclosporine rather than of
the pre-existing cardiac failure.
It has been reported that virtually all cardiac transplant
recipients treated with cyclosporine develop hypertension,
whereas only 20% of the patients treated with azathioprine and
prednisone became hypertensive [29—31]. Our patients had
normal to mildly elevated blood pressure during the follow up
period and seven of them required antihypertensive therapy,
which obtained good control of blood pressure (Fig. 2). Studies
in early stages of established essential hypertension have shown
that GFR is well preserved [32]. Renal deterioration is uncom-
mon in patients with mild hypertension as defined as a diastolic
blood pressure of 90 to 104mm Hg [33]. Most of the patients in
whom renal biopsy was performed after 5 to 10 years of
untreated essential hypertension show slight to moderate arte-
riosclerosis [34], and there is correlation between severity of
pathological changes and degree of hypertension. Other studies
have shown that 15 to 20% with moderate to severe hyperten-
sion have little or no intrarenal vascular disease, and almost
50% do not have changes that could be considered "significant"
[35—37]. If one considers the short duration and the mild degree
of hypertension in our patients, it seems unlikely that the
observed severe renal functional impairment and structural
damage can be attributed to hypertension.
The novelty of the present study consists of the serial section
analysis of individual glomeruli to precisely determine the
extent of the lesions and to calculate glomerular volumes. Using
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this morphometrical technique 102 glomeruli from 10 heart
transplant patients given cyclosporine, 28 glomeruli from con-
trol subjects and 40 glomeruli from patients who died for a
dilatative cardiomyopathy were reconstructed. Forty percent of
glomeruli in renal biopsies taken from cardiac transplant pa-
tients had global or segmental sclerotic changes, while no
glomerulosclerosis was found in any of the two "control" group
glomeruli. This estimation of glomerulosclerosis is at variance
with the data of conventional histological analysis we per-
formed in the same patients. Actually conventional histology
showed sclerotic lesions in only 28.9% of the glomeruli exam-
ined. This difference indicates that the conventional analysis of
renal histological changes based on the examination of selected
8
sections underestimates the actual number of glomeruli affected
by the sclerotic lesions.
In the attempt to quantify the nature of cyclosporine-induced
glomerulopathy Myers and coworkers [16] have measured the
distribution of glomerular cross-sectional areas in heart trans-
plant patients treated with "high" and "low" dose of cyclo-
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sporine. They found that the bell-shaped distribution of glomer-
ular area observed in normal subjects was lost in patients on
cyclosporine for at least 12 months who had an increased
prevalence of smaller and higher than normal glomerular areas.
The authors' interpretation of their findings was that the subset
of glomeruli that had escaped sclerosis underwent hypertrophy
as a possible compensatory mechanism to the loss of filtration
surface by the damaged glomeruli. The results we obtained by
serial section reconstruction of individual glomeruli are remark-
ably similar to those reported by Myers and coworkers [16].
After more than two years of cyclosporine therapy smaller and
larger than normal glomeruli appeared. Thus the relative distri-
bution of the 102 glomeruli analyzed showed that 42.1% were
smaller, and 24.5% were larger than normal range.
The interpretation that the subset of larger than normal
glomeruli had undergone a process of compensatory hypertro-
phy [16] is not in contrast with our findings. In fact, after 31 to
48 months of cyclosporine, none of the hypertrophic glomeruli
had sclerotic lesions, the majority of glomeruli with global or
segmental sclerosis (64.2%) belonging to the subset of small
glomeruli. It is possible that large glomeruli, exposed to major
adaptive hemodynamic changes, will eventually be damaged as
shown in experimental animals with surgical reduction of renal
mass [38, 39]. With time this might lead to an inexorable
progression of the renal damage. However, at the time of the
present analysis we have been unable to find a correlation
between the decline in GFR and the degree of sclerotic lesions
in individual patients, suggesting that the development of gb-
merulosclerosis is not the only factor responsible for the
reduction in GFR. Besides, we have observed a rather impor-
tant reduction of RPF below normal values which could ac-
count, at least partially, for the observed reduction in GFR.
That cyclosporine treatment is associated with a reduction in
RPF has been also reported by Myers et al [16], and it is likely
the consequence of the sustained increase in preglomerular
vascular resistance observed in heart transplant patients given
"low" dose cyclosporine [161. Moreover, there is increasing
experimental evidence that cyclosporine-induced renal impair-
ment is caused by vasoconstriction of afferent arteriole [40].
Signs of glomerular ischemia were the pronounced wrinkling
and thickening of glomerular capillary wall and the marked
hyperplasia of juxtaglomerular apparatus observed in all the
specimens we examined from cyclosporine-treated patients. In
turn glomerular ischemia leads to a reduction of efferent arte-
riolar compliance so that peritubular arteriole perfusion is
reduced. This is the most likely explanation for the lesions
reported by Mihatsch and coworkers some years ago [411 who
described tubulointerstitial lesions characterized by severe tu-
bular atrophy, thickening of tubular basement membrane and
the peculiar striped form of interstitial fibrosis in renal trans-
plant patients on cyclosporine.
In conclusion we have documented that patients with heart
transplantation given cyclosporine at a dose that is considered
"low" by the current standards [14, 16] have major renal
functional and structural changes. Whether more prolonged
treatment would result in progressive and possibly irreversible
renal damage is, at the present, open to speculation. On the
other hand we cannot exclude that patients treated with lower
doses of cyclosporine and/or for shorter periods of time than the
present population of patients may have only mild signs of renal
involvement, or none at all.
The morphometric approach we employed allowed to define
for the first time that beside tubulointerstitial and vascular
changes the chronic treatment with cyclosporine is associated
with a global or segmental glomerulosclerosis which is the likely
consequence of afferent arteriole vasoconstriction. These find-
ings raise the issue of the theoretical benefit of cyclosporine
weighed against its adverse effect on the kidney. We believe
that the risk of cyclosporine nephropathy might be acceptable
for patients with cardiac transplant as long as no alternative
immunosuppressive therapy is practicable. However, treat-
ments for more than two years have to be considered with more
caution to prevent renal allograft rejection, and this kind of
toxicity is probably unacceptable for the prevention of rejection
of isolated pancreas graft in non-uremic diabetics [42].
Reprint requests to Giuseppe Remuzzi, M.D., Mario Negri Institute
for Pharmacological Research, Via Gavazzeni /1, 24100 Bergamo,
Italy.
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